Clinical Guides
Progestogen-Only Contraception: Method Choice, Eligibility and Safe Follow-up
An India-contextualised educational guide to progestogen-only contraceptive methods, individual eligibility and safety-netting; it is not a personal prescription, device-insertion instruction or substitute for current local policy.
MedNext Academy | 15 min read
Progestogen-Only Contraception: Method Choice, Eligibility and Safe Follow-up
An India-contextualised educational guide to progestogen-only contraceptive methods, individual eligibility and safety-netting; it is not a personal prescription, device-insertion instruction or substitute for current local policy.
Summary
Progestogen-only contraception (POC) contains a progestogen without oestrogen. The family includes progestogen-only pills (POPs), depot or other injectable contraceptives, subdermal implants and levonorgestrel-releasing intrauterine systems (LNG-IUS), although exact products, licensing, programme supply and trained-provider access vary. These methods differ substantially in how they are used, how quickly fertility returns after stopping, expected bleeding changes, duration, procedure requirements and failure patterns. They should not be described as one interchangeable option simply because they lack oestrogen.
POC is particularly important when a combined hormonal method is unsuitable or when a person prefers to avoid oestrogen. It may be appropriate in many situations where oestrogen-related thrombotic risk makes combined hormonal contraception less suitable, but it still requires a method-specific eligibility assessment. Pregnancy possibility, postpartum and breastfeeding timing, current bleeding, breast cancer, serious liver disease, cardiovascular disease, drug interactions, bone-health considerations for some injectable methods, infection risk for intrauterine methods and ability to attend follow-up can all matter.
WHO Medical Eligibility Criteria (MEC) asks whether a method is medically safe in defined conditions. WHO Selected Practice Recommendations (SPR) addresses safe initiation, continuation and management once eligibility is established. Neither document replaces national protocols, product information or clinical judgement. A high-quality consultation explains advantages and limits, asks what matters to the person, checks for red flags, gives method-specific instructions, offers condoms when STI prevention is needed and records a review plan.
This guide uses educational safety language. It does not recommend a brand, dose, injection schedule, insertion technique or unsupervised response to missed pills, late injections or a suspected device problem.
How Common Is It?
Progestogen-only methods form an important part of modern contraception, yet there is no single frequency estimate that captures use across all Indian communities, facilities and time periods. Uptake is influenced by availability, counselling quality, public-sector supply, out-of-pocket cost, geographic access, confidence in privacy, procedure availability and individual fertility preferences. A report of a method dispensed or inserted does not show whether the person was able to continue it comfortably, obtain follow-up or change method without pressure.
The clinical burden is not only unintended pregnancy. Users may seek POC for contraception alongside heavy menstrual bleeding, dysmenorrhoea, postpartum contraception or a need to avoid oestrogen. Others may discontinue because of irregular bleeding, amenorrhoea, acne, mood concerns, headaches, injection visits or a wish to conceive. These experiences deserve explanation and choice rather than dismissal. Expected bleeding change is common with several POC methods, but severe, persistent, new or pregnancy-associated bleeding still needs assessment.
Method effectiveness depends on the method and real-world use. A daily pill depends on consistent use and can be affected by missed doses or gastrointestinal illness; an injection depends on attendance at the correct interval; a device or implant depends on correct insertion, documentation and removal access. It is therefore unsafe to promise identical effectiveness or convenience across all POC options. Use a current method-specific source during counselling.
For examinations, separate method prevalence from medical eligibility. WHO MEC categories apply to a condition and a specific method, so an eligibility judgement for a POP cannot automatically be transferred to DMPA, an implant or an LNG-IUS. The patient's preference and local service capability remain part of good care.
Risk Factors
The key risk question is method-specific. Progestogen-only methods avoid oestrogen exposure, but this does not mean that every POC is safe for every person. Ask about current or previous breast cancer, serious liver disease or liver tumour, unexplained vaginal bleeding, known pregnancy, hypersensitivity, severe cardiovascular disease, diabetes complications, thrombotic history, migraine, hypertension and current medicines. Interpret the answers with the current MEC recommendation for the proposed method rather than using the phrase “progestogen-only is always safe”.
For injectables, ask about future fertility timing, bleeding preference, ability to return for repeat dosing, nutritional and bone-health context, fractures, chronic steroid exposure and adolescence where relevant. Do not turn a concern about bone health into an automatic refusal; assess the person, the duration of use, alternatives and current guidance. For implants, ask about planned access for removal and medicines that may lower hormonal effectiveness. For LNG-IUS, take a pregnancy, infection, uterine-cavity and bleeding history and ensure that insertion can be performed by a trained provider with a referral pathway.
Medication review is essential. Some enzyme-inducing antiseizure, tuberculosis, antiretroviral or herbal medicines can reduce the effectiveness of particular hormonal methods. The interaction is not identical across every POC formulation. Verify the current product information and obtain family-planning or specialist advice rather than telling a person to stop an essential medicine or relying on a memorised list. Ask directly about non-prescription and traditional treatments.
Social risks also affect continuation. Coercion, intimate-partner violence, inability to attend appointments, lack of private medicine storage, disability, literacy and migration may affect whether a daily, provider-dependent or long-acting method is practical. Respectful counselling offers alternatives and safeguards confidentiality; it does not assume that a person's age, marital status or parity determines their appropriate method.
Diagnosis
A request for a progestogen-only method is a contraceptive assessment rather than a disease diagnosis. The clinician's task is to establish pregnancy possibility, identify a safe method, understand the person's goals and recognise symptoms that need diagnostic care before a method is started or continued. Begin by asking why POC is being considered: pregnancy prevention, breastfeeding, a contraindication to oestrogen, menstrual management, a switch after a side effect, need for privacy or a long-acting option. The answer guides method selection but must not replace medical screening.
History
Ask about last menstrual bleeding, cycle pattern, unprotected intercourse, emergency contraception, current method, missed or late use, vomiting or diarrhoea for an oral method, recent pregnancy outcome, breastfeeding and future pregnancy plans. Record past contraception, bleeding changes, adverse effects, insertion or removal experiences and reasons for discontinuation. Ask about breast cancer, liver disease, thrombosis, cardiovascular disease, migraine, hypertension, diabetes, unexplained bleeding, pelvic infection or STI risk, uterine problems, medicines and allergies. Establish any symptoms of pregnancy, ectopic pregnancy, severe infection or haemodynamic compromise.
Examination
Measure blood pressure and conduct targeted examination when the history indicates it, even though oestrogen is absent. Assess for pallor, abdominal tenderness, fever, jaundice, a mass, neurologic symptoms or signs of infection when relevant. A pelvic examination is required when it is clinically indicated for symptoms or an intrauterine method, but it is not a routine precondition for every pill, injection or implant request. For a possible device insertion, use consent, privacy, infection prevention, a chaperone where appropriate and trained assessment of whether insertion is safe.
Investigations
Use a pregnancy test when history and timing do not make pregnancy reasonably unlikely, and urgently assess pain, bleeding, syncope or shoulder-tip pain. STI testing, cervical assessment, haemoglobin, ultrasound or other tests are directed by symptoms and risk, not imposed as a barrier to contraception. Liver tests, metabolic tests, imaging or specialist review are indicated by history or findings. Before an intrauterine method, investigate a current pelvic infection, abnormal bleeding or suspected uterine pathology according to the local pathway; do not use device insertion as a substitute for diagnosis.
Differential Diagnosis
Irregular bleeding during POC use has a broad differential. It may be an expected method effect, particularly early after initiation, but pregnancy including ectopic pregnancy, poor adherence to a pill, a late injection, interacting medicines, cervicitis or another STI, structural uterine disease, cervical pathology, thyroid disease or perimenopause can coexist. Establish onset, severity, change from baseline, relationship to method initiation, pain, discharge, pregnancy risk and systemic symptoms. Do not label all bleeding “hormonal” before assessing red flags.
Amenorrhoea can be an expected outcome with some POC methods and is not itself harmful, but pregnancy should be excluded when use has been inconsistent or symptoms suggest it. New nausea, breast tenderness or pelvic pain need context rather than reassurance by text message alone. A positive pregnancy test in a user of any method needs appropriate assessment of pregnancy location and options; it should not provoke blame or unsupported claims about fetal harm.
Pelvic pain, fever, purulent discharge, cervical motion tenderness, severe abdominal tenderness or a toxic appearance suggests infection or another acute pelvic condition. With an intrauterine method, consider but do not presume expulsion, malposition or perforation if there is pain, bleeding, missing strings or a pregnancy concern. These conditions require trained clinical assessment and appropriate imaging or referral; self-examination cannot reliably establish safety.
Headache, mood symptoms, acne or weight change are commonly attributed to hormones but may have other causes. Review temporal relation, severity, medicines, sleep, nutrition, mental health, blood pressure and neurological features. Serious new headache, focal symptoms, chest symptoms, jaundice or severe depression with safety concerns requires assessment, not simply a switch to another hormonal product.
Management
Management starts with informed, voluntary method choice. Explain the difference between a daily POP, an injection, an implant and an LNG-IUS: whether a procedure is needed, who can provide it, how long it lasts, expected bleeding changes, return-to-fertility considerations, need for repeat attendance, removal access, interactions and whether it protects against STIs. Offer condoms when STI prevention is relevant and explain that emergency contraception is a separate intervention after unprotected intercourse or method failure. A patient should be able to choose, decline or change a method without coercion.
Once an appropriate method is selected, use the exact current local protocol and product information for initiation, backup contraception if needed, missed or delayed use, repeat injection timing, device checks, expected bleeding and follow-up. These instructions are formulation-specific. A daily pill schedule must not be applied to every POP, and an implant or LNG-IUS should not be represented as maintenance-free if a person cannot access removal or review. Give written, translated or otherwise accessible information and document how the person can obtain urgent help.
Counsel about bleeding proactively. Explain that irregular or absent bleeding can occur and does not by itself prove pregnancy, infertility or blood accumulation. Encourage review for bleeding that is heavy, prolonged, postcoital, painful, new after a stable pattern or associated with pregnancy symptoms, fever or discharge. Management of troublesome bleeding depends on the method, duration, contraindications and diagnosis; it should follow a current protocol rather than an internet remedy.
Review at a clinically appropriate interval or earlier if a medical condition, medicine, bleeding pattern, fertility intention or preference changes. If POC is unsuitable or unacceptable, offer another reversible or permanent method based on the person's goals. Switching must include a pregnancy-risk plan, not merely removal or discontinuation of the current method.
Prescribing Information
This section provides a safety framework, not a regimen. Before prescribing a POP or injection, or arranging an implant or LNG-IUS, document the proposed method, indication, pregnancy assessment, relevant MEC conditions, bleeding history, breast and liver history, medicines, allergies, breastfeeding or postpartum context, consent and planned follow-up. For an implant or intrauterine method, document trained-provider assessment, insertion details, product batch or device information where required by local policy, and a route for removal or complication review.
WHO MEC categories are method-specific. Category 1 means no restriction; category 2 means advantages generally outweigh risks; category 3 means risks usually outweigh advantages; category 4 means unacceptable health risk. A person can be eligible for one progestogen-only method and not another. Assess all relevant conditions together and seek expert advice for uncertainty, especially in current or prior breast cancer, serious liver disease, complex cardiovascular disease, interacting medication or a difficult postpartum scenario.
Do not give a generic dose, injection interval or missed-dose rule in an educational article. Products vary in progestogen, route, duration and licensed instructions. Verify the local label and the WHO SPR-adapted pathway, including what to do after vomiting or diarrhoea, a delayed injection, a suspected expulsion, a missing implant, an interaction or a planned switch. A delayed injection or missed pill may create pregnancy risk; the response should be timely and method-specific.
Explain expected effects and urgent symptoms: severe lower-abdominal pain, pregnancy symptoms, heavy bleeding with collapse, fever or severe pelvic pain, jaundice, severe new neurological symptoms or a serious allergic reaction. Document counselling on STI protection, warning symptoms, emergency contraception where relevant and how to get help. Do not prescribe a hormonal method repeatedly without reassessing changed health conditions or medicines.
When to Refer
Urgently refer or send to emergency care for haemodynamic instability, heavy bleeding with dizziness or syncope, pregnancy possibility plus severe abdominal or pelvic pain, shoulder-tip pain, collapse, peritonism, suspected ectopic pregnancy, sepsis, severe allergic reaction, acute jaundice or serious new neurological symptoms. These presentations require diagnostic assessment and stabilisation rather than routine contraceptive review. A patient with a current intrauterine method and pregnancy symptoms needs timely assessment of pregnancy location.
Refer to experienced family-planning, gynaecology, obstetric, oncology, hepatology, neurology, cardiology or other specialist care when eligibility is uncertain due to breast cancer, complex liver disease, severe cardiovascular disease, difficult migraine history, interacting medicines, suspected uterine distortion, complicated postpartum circumstances or a history of serious method-related complication. The referral question should be explicit: suitability of a method, evaluation of symptoms, removal, insertion planning or all of these.
Refer for persistent, heavy, postcoital, painful or unexplained bleeding; recurrent pelvic infection; suspected implant complication; non-palpable implant; missing intrauterine threads with symptoms; suspected expulsion; inability to remove a device; or a person who wants removal but cannot obtain it safely. Long-acting contraception is only ethically sound when discontinuation and removal are accessible.
Include the exact method, date of start or insertion, documented injection dates or pill adherence, pregnancy test if done, symptoms, examination findings, blood-pressure readings, medical history and medicine list. Make referral usable by addressing transport, language, disability, safety and confidentiality barriers. Delaying a referral because contraception is an elective request can miss a significant diagnosis.
Red Flags
Pregnancy possibility with unilateral pelvic pain, severe abdominal pain, shoulder-tip pain, fainting, collapse or vaginal bleeding is a red flag for ectopic pregnancy and needs urgent assessment. Heavy bleeding with pallor, dizziness or haemodynamic compromise is an emergency regardless of contraceptive method. Fever, rigors, purulent discharge, escalating pelvic pain, guarding or a toxic appearance needs assessment for pelvic infection or another acute abdominal condition.
With an implant, sudden inability to feel a previously palpable implant, local redness, marked pain, swelling, wound discharge, neurological symptoms in the limb or concern about migration requires review. With an intrauterine method, severe pain, a new pregnancy concern, missing strings, suspected expulsion, fever or foul discharge should trigger trained assessment. Do not attempt to remove an implant or intrauterine system outside an appropriately equipped service.
A new breast mass, jaundice, severe right-upper-quadrant pain, severe depression with self-harm thoughts, focal neurological symptoms or a serious allergic reaction warrants prompt medical assessment. These symptoms do not automatically prove that POC is the cause, but they make a routine refill or remote reassurance unsafe. An unexplained change in bleeding after a stable pattern also merits review.
Consent and safeguarding are red flags when a partner, family member or authority is pressuring a person to start, continue or remove contraception. Offer a private conversation if safe, use trauma-informed communication and follow local safeguarding policy. Never make a method conditional on a pelvic examination, a partner's permission, marital status, parity, STI disclosure or a promise not to become pregnant.
Indian Clinical Context
The National Health Mission (NHM) maintains family-planning guidance and lists resources on oral pills, injectable contraception and intrauterine contraception. These programme resources demonstrate that method counselling and service delivery are organised through different channels and levels of care. However, the online guideline index does not establish that every product, pack, device, trained provider or removal service is available in every state, district or facility. This guide therefore does not claim universal Indian availability, cost, brand, programme entitlement or a locally valid injection schedule.
WHO MEC and SPR are global normative documents intended for adaptation by national programmes. For Indian practice, use them to structure eligibility and counselling, then verify current national, state, district and facility instructions, approved product information and referral access. A dated manual can be useful for teaching a method class but should not be used alone to make a current prescribing decision. This is particularly important for product-specific POP instructions, injections, implants and intrauterine systems.
Access considerations matter. A daily method may be difficult to store privately; a repeat injection may require travel; an implant or LNG-IUS requires trained insertion and guaranteed removal access. Stigma, language, disability, cash cost, transport and fear of disclosure can affect informed continuation. Offer accessible information, privacy and a real alternative rather than treating non-adherence as non-compliance or insisting on a clinician's preferred method.
In resource-constrained services, the minimum safe pathway is to assess pregnancy possibility and red flags, take relevant medical and medicine history, use current guidance, give STI-protection advice where appropriate, document consent and arrange referral when a method or symptom lies beyond service capacity. Absence of a procedure service should not become absence of contraceptive counselling.
NMC Competency Mapping
The National Medical Commission Competency Based Medical Education Curriculum 2024 expects graduates to provide respectful reproductive-health care, use investigations appropriately, prescribe safely, communicate risk and recognise when referral is required. Progestogen-only contraception is a practical integration of those competencies because selection depends on health status, patient priorities, informed consent and access to follow-up rather than on a one-size-fits-all product choice.
At the Know level, learners should distinguish a POP, injectable, implant and LNG-IUS from one another and from combined hormonal and emergency methods. They should understand that POC has no oestrogen but still has method-specific contraindications, interactions, bleeding effects and follow-up needs. They should explain the purpose of WHO MEC categories and why a global guideline needs local implementation.
At the Know How level, learners should assess pregnancy possibility, postpartum and breastfeeding context, medical history, medicines, abnormal bleeding, infection symptoms and the person's priorities. They should recognise why a pregnancy test, pelvic examination, laboratory study or imaging is sometimes indicated and sometimes not. They should counsel on method-specific adherence, bleeding, STI prevention, warning symptoms and removal access without coercion or stigma.
At the Show How level, a learner should obtain consent, protect privacy, document a safety assessment, give a method-specific follow-up plan and make a timely referral for acute symptoms or uncertain eligibility. Insertion and removal procedures require the appropriate trained supervision and local credentialing. No invented NMC competency code is assigned; institutions should map this material to their current approved competency ledger.
Key Exam Pearls for NEET PG
Progestogen-only contraception includes pills, injections, implants and LNG-IUS; it is not a synonym for a single “mini-pill”. Methods differ in administration, duration, bleeding pattern, return to fertility, interactions, procedure needs and follow-up. Do not apply a missed-pill rule to an injection, implant or intrauterine method.
POC avoids oestrogen, so it is often considered when combined hormonal contraception is unsuitable, but it is not automatically safe in all conditions. Use WHO MEC method-specific categories: category 1 has no restriction, category 2 usually permits use, category 3 usually favours another method and category 4 is an unacceptable risk. Apply more than one relevant condition together.
Before initiation or continuation, establish pregnancy possibility and assess bleeding, breast cancer and liver history, medicines and current health conditions. For an intrauterine method, also assess infection, uterine and pregnancy considerations through a trained service. Pelvic examination, routine laboratory screening and imaging are not universal prerequisites for every POC request; investigate according to the clinical question.
Irregular bleeding or amenorrhoea can be expected with POC, but persistent, heavy, painful, postcoital or pregnancy-associated bleeding needs assessment. Pregnancy possibility with acute pelvic pain, shoulder-tip pain, syncope or bleeding is an ectopic-pregnancy emergency. Fever, purulent discharge and severe pelvic tenderness suggest infection or another acute condition.
Counselling must cover method-specific use, access to removal, expected bleeding, STI protection and emergency contraception after relevant failure. Use current WHO SPR-adapted local instructions rather than memorising a generic schedule. A patient may choose another method or decline contraception; voluntary informed choice is a clinical requirement, not an optional extra.
Frequently Asked Questions
Are all progestogen-only contraceptive methods safe during breastfeeding?
Progestogen-only methods are often considered in postpartum and breastfeeding care, but timing, individual medical conditions, local guidance and the specific method still matter. A clinician should assess pregnancy status, postpartum timing, breastfeeding circumstances, health history and the available product before advising. Do not transfer advice from one progestogen-only method or country protocol directly to another.
Does absent bleeding on a progestogen-only method cause harm?
Amenorrhoea can occur with several progestogen-only methods and does not mean blood is accumulating inside the body. However, pregnancy should be considered if use has been inconsistent or symptoms suggest it, and new pain, heavy bleeding, dizziness, fever or a major change after a stable pattern requires assessment. Individual concerns deserve explanation rather than reassurance without review.
Can someone switch from combined pills to progestogen-only contraception immediately?
Switching can sometimes be straightforward, but exact timing, backup protection and pregnancy assessment depend on the method being left, the progestogen-only method being started, recent intercourse and correct use. The current product instructions and local protocol should be checked. Stopping a combined method without a plan can create unintended pregnancy risk, so tailored counselling is important.
Why is access to removal important for implants and LNG-IUS?
Long-acting contraception remains voluntary only when a person can obtain removal or clinical review when they want it or when symptoms occur. Implant and LNG-IUS insertion should include clear documentation, counselling about expected changes and a realistic pathway for removal. A service should not promote a long-acting method without planning for complications, discontinuation and referral.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic